Product Description
The research-grade biosimilar is a humanized recombinant IgG1 monoclonal antibody that specifically targets the scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. CD6 is a co-stimulatory molecule that is primarily expressed on the T-cell surface and plays an important role in the maturation, activation, and differentiation of T-cells, and pro-inflammatory cytokine production. Binding of Itolizumab to CD6 prevents T-cell activation, decreases the levels of IFN-?, IL-6, and TNF-? and thus reduces inflammation. The original drug was approved by the DCGI in India to treat moderate-to-severe plaque psoriasis. In 2020, the drug received approval to treat moderate-to-severe COVID-19 complications.
Biovision | A2164 | Anti-CD6 (Itolizumab), Humanized Antibody DataSheet
Antibody Target: CD6
Target Alternative Name: T1h, XQQ2RHV14N, TP120, T12
Tag Line: The biosimilar is a humanized monoclonal antibody that targets CD6 and inhibits T-cell activation and thus reduces inflammation
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human CD6
Accession #:
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE